SYSTEMATIC REVIEW

The association between therapeutic plasma exchange and the risk of mortality among patients critically ill with COVID-19: a meta-analysis [version 1; peer review: 2 approved, 2 approved with reservations]

Shinta Oktya Wardhani ¹, Jonny Karunia Fajar ², Gatot Soegiarto ³,
Laksmi Wulandari⁴, Helnida Anggun Maliga ⁵, Muhammad Ilmawan ⁵,
Risna Merysa⁶, Arlentina Bentivolita Simamora², Qurrata Aini⁶,
Komang Noviantari⁶, Ayu Widya Lestari⁷, Maria Yoheni Harnila⁶, Imam Syafi'i⁸,
Jane Andrea Christiano Djianzonie⁹, Nenci Siagian ¹⁰, Sri Nining⁶,
Risyda Zakiyah Hanim⁶, Wahyuni Wahyuni¹¹, Fitri Aulia¹¹, Juliansyah Juliansyah⁶,
Reflin Mahmud⁶, Fredo Tamara ², Aditya Indra Mahendra ²,
Amanda Cininta Wowor², Fikri Baladraf², Ponda Hernest Hadinata²,
Adhityari Ikkeputri², Hana Nadya², Dessy Aprilia Kartini ⁵, Milda Husnah^{12,13},
Firzan Nainu ¹⁴, Harapan Harapan ^{12,15,16}

¹Medical Research Unit, School of Medicine, Universitas Syiah Kuala, Banda Aceh, Aceh, 23111, Indonesia

²Faculty of Mathematics and Natural Sciences, Universitas Syiah Kuala, Banda Aceh, Aceh, 23111, Indonesia

³Faculty of Pharmacy, Hasanuddin University, Makassar, 90245, Indonesia

⁴Tropical Disease Centre, School of Medicine, Universitas Syiah Kuala, Banda Aceh, Aceh, 23111, Indonesia

⁵Department of Microbiology, School of Medicine, Universitas Syiah Kuala, Banda Aceh, Aceh, 23111, Indonesia

⁶Division of Hematology and Oncology, Department of Internal Medicine, Faculty of Medicine, Universitas Brawijaya, Malang, East Java, 65145, Indonesia

⁷Brawijaya Internal Medicine Research Center, Department of Internal Medicine, Faculty of Medicine, Universitas Brawijaya, Malang, East Java, 65145, Indonesia

⁸Division of Allergy & Immunology, Department of Internal Medicine, Faculty of Medicine, Universitas Airlangga, Surabaya, East Java, 60286, Indonesia

⁹Department of Pulmonology and Respiratory Medicine, Faculty of Medicine, Universitas Airlangga, Surabaya, East Java, 60286, Indonesia

¹⁰Faculty of Medicine, Universitas Brawijaya, Malang, East Java, 65145, Indonesia

¹¹Faculty of Nursing, Universitas Indonesia, Jakarta, 10430, Indonesia

¹²Faculty of Nursing, Universitas Syiah Kuala, Banda Aceh, Aceh, 23111, Indonesia

¹³Faculty of Pharmacy, Universitas Indonesia, Jakarta, 10430, Indonesia

¹⁴Department of Internal Medicine, Faculty of Medicine, Universitas Indonesia, Jakarta, 10430, Indonesia

¹⁵Department of Internal Medicine, Faculty of Medicine, Universitas Airlangga, Surabaya, East Java, 60286, Indonesia

¹⁶Faculty of Public Health, Universitas Indonesia, Jakarta, 10430, Indonesia

V1 First published: 14 Dec 2021, 10:1280
<https://doi.org/10.12688/f1000research.74972.1>

Latest published: 14 Dec 2021, 10:1280
<https://doi.org/10.12688/f1000research.74972.1>

Open Peer Review

Abstract

Background: Cytokine storm has been widely known to contribute to the development of the critical condition in patients with coronavirus disease 2019 (COVID-19), and studies had been conducted to assess the potential aspect of cytokine storm elimination by performing therapeutic plasma exchange (TPE). However, contradictory findings were observed. The objective of this study was to assess the association between TPE and the reduction of mortality of critically ill COVID-19 patients.

Methods: A meta-analysis was conducted by collecting data from PubMed, Scopus, and Web of Science. Data on the mortality rate of critically ill COVID-19 patients treated with TPE plus standard of care and that of patients treated with standard of care alone were analyzed using a Z test.

Results: We included a total of four papers assessing the association between TPE and the risk of mortality among critically ill COVID-19 patients. Our findings suggested that critically ill COVID-19 patients treated with TPE had lower risk of mortality compared to those without TPE treatment.

Conclusion: Our study has identified the potential benefits of TPE in reducing the risk of mortality among critically ill COVID-19 patients.

Keywords

COVID-19; therapeutic plasma exchange; cytokine storm; treatment

This article is included in the **Emerging Diseases and Outbreaks** gateway.

This article is included in the **Coronavirus** collection.

Approval Status ✓ ? ✓ ?

	1	2	3	4
version 1	✓	?	✓	?
14 Dec 2021	view	view	view	view

1. **Seyi Samson Enitan** , Babcock University, Ilishan-Remo, Nigeria
2. **Guilherme Welter Wendt** , Universidade Estadual do Oeste do Paraná (UNIOESTE), Francisco Beltrão, Brazil
3. **Mahir Gachabayov** , New York Medical College, Valhalla, USA
4. **Ashish Kumar** , St Johns's Medical College Hospital, Bangalore, India

Any reports and responses or comments on the article can be found at the end of the article.

Corresponding authors: Shinta Oktya Wardhani (shinta_oktya.fk@ub.ac.id), Jonny Karunia Fajar (gembyok@gmail.com), Gatot Soegiarto (gatot_soegiarto@fk.unair.ac.id)

Author roles: **Wardhani SO:** Conceptualization, Investigation, Methodology, Supervision, Validation; **Fajar JK:** Conceptualization, Investigation, Methodology, Supervision, Validation; **Soegiarto G:** Conceptualization, Formal Analysis, Investigation, Methodology, Supervision, Validation; **Wulandari L:** Supervision, Validation; **Maliga HA:** Conceptualization, Methodology, Validation; **Ilmawan M:** Formal Analysis, Investigation, Methodology, Software, Writing – Original Draft Preparation; **Merysa R:** Data Curation, Project Administration, Resources, Visualization; **Simamora AB:** Data Curation, Investigation, Project Administration, Resources, Visualization; **Aini Q:** Data Curation, Investigation, Project Administration, Resources, Validation; **Noviantari K:** Data Curation, Investigation, Project Administration, Software, Visualization; **Lestari AW:** Data Curation, Investigation, Project Administration, Resources, Visualization; **Harnila MY:** Data Curation, Investigation, Project Administration, Resources, Visualization; **Syafi'i I:** Data Curation, Investigation, Project Administration, Resources, Visualization; **Djanzonie JAC:** Data Curation, Project Administration, Resources, Visualization; **Siagian N:** Data Curation, Project Administration, Resources, Visualization; **Nining S:** Data Curation, Project Administration, Resources, Visualization; **Hanim RZ:** Data Curation, Project Administration, Resources, Visualization; **Wahyuni W:** Data Curation, Project Administration, Resources, Visualization; **Aulia F:** Data Curation, Project Administration, Resources, Visualization; **Juliansyah J:** Data Curation, Project Administration, Resources, Visualization; **Mahmud R:** Data Curation, Project Administration, Resources, Visualization; **Tamara F:** Data Curation, Project Administration, Resources, Visualization; **Mahendra AI:** Data Curation, Project Administration, Resources, Visualization; **Wowor AC:** Data Curation, Project Administration, Resources, Visualization; **Baladraf F:** Data Curation, Project Administration, Resources, Visualization; **Hadinata PH:** Data Curation, Project Administration, Resources, Visualization; **Ikkeputri A:** Data Curation, Project Administration, Resources, Visualization; **Nadya H:** Data Curation, Project Administration, Resources, Visualization; **Kartini DA:** Data Curation, Project Administration, Resources, Visualization; **Husnah M:** Data Curation, Project Administration, Resources, Visualization; **Nainu F:** Data Curation, Project Administration, Resources, Visualization; **Harapan H:** Supervision, Validation, Visualization, Writing – Original Draft Preparation, Writing – Review & Editing

Competing interests: No competing interests were disclosed.

Grant information: The author(s) declared that no grants were involved in supporting this work.

Copyright: © 2021 Wardhani SO *et al.* This is an open access article distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite this article: Wardhani SO, Fajar JK, Soegiarto G *et al.* **The association between therapeutic plasma exchange and the risk of mortality among patients critically ill with COVID-19: a meta-analysis [version 1; peer review: 2 approved, 2 approved with reservations]** F1000Research 2021, 10:1280 <https://doi.org/10.12688/f1000research.74972.1>

First published: 14 Dec 2021, 10:1280 <https://doi.org/10.12688/f1000research.74972.1>

Introduction

Since first reported in December 2019,¹ coronavirus disease 2019 (COVID-19) has become an unresolved global pandemic. The challenge of the pandemic management at the present time might be due to the fact that a number of mutations have occurred making the virus more transmissible and causing critical illness.² The World Health Organization (WHO) has established a living guideline on drugs for the management of COVID-19³ and updated it periodically. However, the treatment of critically ill COVID-19 patients remains a serious issue.⁴ Patients critically ill with COVID-19 have been widely reported to have a poor prognosis, and theory reveals that cytokine storm might underlie this mechanism. In a cytokine storm excessive accumulation of pro-inflammatory cytokines might be responsible for the poor prognosis of COVID-19 patients. No study has found an effective treatment for the management of a cytokine storm in patients critically ill with COVID-19. Therefore, an investigation into the treatment that acts to remove these pro-inflammatory cytokines, for example, using therapeutic plasma exchange (TPE) may be required.

Since first introduced in 1952, TPE has been shown to provide an excellent outcome in patients with multiple myeloma to control hyperviscosity.⁵ Moreover, the implementation of this therapeutic treatment has also been reported in an *Escherichia coli* outbreak,⁶ a Shigella infection,⁷ infectious toxicosis,⁸ and septic shock with multiple organ failure⁹; and reduced risk of mortality was revealed. In the case of COVID-19, the US Food and Drug Administration (FDA) has posited that TPE may have a role as a rescue therapy in critically ill patients with COVID-19.¹⁰ However, insufficient evidence has resulted in indecision in applying TPE for the management of critically ill COVID-19 patients. To date, TPE has been studied in Oman,¹¹ Turkey,¹² Pakistan,¹³ and Saudi Arabia.¹⁴ However, contradictory findings exist. Therefore, our study aimed to assess the potential of TPE in reducing mortality of critically ill COVID-19 patients using a meta-analysis approach. The findings might add new insight and clarify the true potency of TPE for treating patients critically ill with COVID-19.

Methods

Study design

From March to August 2021, a meta-analysis following the protocols of the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA)¹⁵ was conducted to evaluate the effectiveness of TPE in reducing the mortality rate of critical COVID-19 patients. The PRISMA checklist in our present study is presented as extended data in Figshare.¹⁶ The major databases including PubMed, Scopus, and Web of Science were used to search for potential articles.

Eligibility criteria

Inclusion and exclusion criteria were defined to assess relevant articles. The inclusion criteria of the study were (1) observational or randomized controlled trial studies, (2) having adequate information to calculate the potential association and effect estimates, and (3) applying a well-defined methodological approach to establish a COVID-19 diagnosis. All case reports, case series, letters to the editor, reviews, and commentaries, as well as studies with pre-post test comparison, and poor-quality methodology assessed with the Newcastle-Ottawa scale (NOS) were excluded.

Search strategy and data extraction

The source databases used in our study were PubMed, Scopus, and Web of Science. We restricted the searching period up to 28 July 2021, and the language was English only. The Medical Subject Headings were: (“COVID-19” or “SARS-CoV-2”) and (“plasma exchange” or “therapeutic plasma exchange” or “TPE”). The reference lists of all potential related articles were also assessed to retrieve additional relevant articles. Data extraction was performed for all included papers, including: (1) name of the first author; (2) year of publication; (3) country of origin; (4) sample size of cases and controls, (5) TPE, and (6) mortality rate between groups.

Assessment of the methodology quality

All included articles were assessed for their quality using NOS for observational studies¹⁷ and the Jada-modified scale for RCTs.¹⁸ The article quality was interpreted as low, moderate, and high. Low quality articles were excluded from our study. The assessment was performed by two independent authors (MI, HAM), and when a discrepancy was observed an assessment by a senior researcher (JKF) was conducted.

Outcome measure

The main outcome of the study was all causes of mortality among critical COVID-19 patients treated with and without TPE. The diagnosis of COVID-19 was established by using RT-PCR of SARS-CoV-2 RNA from nasal or oropharyngeal swab samples, and critical COVID-19 patients were defined by following the guideline (requires life sustaining treatment, acute respiratory distress syndrome, sepsis, or septic shock).^{3,19}

Statistical analysis

The calculation of potential publication bias, heterogeneity among studies, and the association between the use of TPE and the risk of mortality among patients with COVID-19 were assessed using an Egger test, a Q test, and a Z test; respectively. The Egger test with a p-value more than 0.05 indicated the presence of potential publication bias. Moreover, the heterogeneity among studies was considered when the p-value of a Q test indicated less than 0.10. The pooled association was calculated using a Z test, where the p-value of less than 0.05 indicates a significant association. The estimated effect was presented as an odds ratio with 95% confidence interval (OR 95% CI). The cumulative calculation was presented as a forest plot. An R package software ([R Studio version 4.1.1](#), MA, USA, (RRID:SCR_000432)) was used to perform the analyses.

Results

Studies selection

We identified a total of 255 papers. Among them, four papers were excluded due to duplication and additional 227 papers due to irrelevant context. There were 24 papers in total included for full-text assessment. Then, 20 of the 24 papers were

Figure 1. Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flowchart of article selection in our meta-analysis.

Table 1. Baseline characteristics of articles included in our study.

Study and year	Country	Study design	Quality	TPE		Control	
				Total	Mortality	Total	Mortality
Khamis <i>et al.</i> , 2020 ¹¹	Oman	Cohort Retrospective	High	11	1	20	9
Gucyetmez <i>et al.</i> , 2020 ¹²	Turkey	Cohort Retrospective	Moderate	12	1	12	7
Kamran <i>et al.</i> , 2020 ¹³	Pakistan	Cohort Retrospective	High	45	4	45	18
Faqihi <i>et al.</i> , 2020 ¹⁴	Saudi Arabia	RCT	High	43	9	44	15

Source	OR (95% CI)
Khamis <i>et al.</i> , 2020	0.08 [0.00; 1.52]
Kamran <i>et al.</i> , 2020	0.16 [0.05; 0.50]
Faqihi <i>et al.</i> , 2020	0.18 [0.07; 0.45]
Gucyermez <i>et al.</i> , 2020	0.27 [0.07; 1.01]
Keith <i>et al.</i> , 2020	0.37 [0.15; 0.90]
Total	0.22 [0.13; 0.39]
Heterogeneity: $\chi^2_4 = 2.30$ ($P = .68$), $I^2 = 0\%$	
Test for overall effect: $t_4 = -7.45$ ($P = .002$)

Figure 2. Forest plot of mortality rate between therapeutic plasma exchange vs control (OR: 0.2097; 95% CI: 0.0516, 0.852; p-value: 0.0382; pHet: 0.2065; pE: 0.2153).

further excluded since 18 were reviews and case reports and two papers had insufficient data. Four papers were included in the final analysis.^{11–14} The article selection PRISMA flowchart is presented in Figure 1 and the baseline characteristics are described in Table 1.

TPE treatment and COVID-19 mortality rate

A total of 111 COVID-19 patients treated with TPE and 121 COVID-19 patients without TPE, retrieved from three retrospective cohort studies and one RCT, were included in our analysis. Our results found that COVID-19 patients treated with TPE had reduced mortality rate compared to COVID-19 patients without TPE treatment (OR: 0.21; 95% CI: 0.05, 0.85) (Figure 2).

Heterogeneity and potency of bias across the studies

Our analysis revealed the absence of the evidence of heterogeneity. Therefore, we applied a fixed-effect model to assess the correlation. For the potency of bias assessment across the studies, our analysis using an Egger test found no publication bias.

Discussion

Our study identified that TPE treatment in critically ill COVID-19 patients reduced the mortality rate. To date, our study is the first meta-analysis to report on the use of TPE for the management of COVID-19. In our analyses, we included four studies from Oman,¹¹ Turkey,¹² Pakistan,¹³ and Saudi Arabia¹⁴; and all reports revealed similar findings in which TPE treatment reduced mortality among patients with COVID-19. TPE has been applied and proved to reduce the risk of mortality in the management of several infectious diseases, such as *Escherichia coli* O157:H7-associated hemolytic uremic syndrome,^{6,20} Shigella infection,⁷ infectious toxicosis,⁸ HIV infection,²¹ peripheral HIV neuropathy,²² Kaposi's sarcoma,²¹ disseminated cryptococcosis,²³ and septic shock with multiple organ failure.⁹ Moreover, in the case of the *Escherichia coli* O157 outbreak in 1996, TPE proved beneficial in the reduction of mortality.⁶ Therefore, as suggested in our study, TPE might possess potential benefits in COVID-19 treatment.

The precise mechanism of how TPE benefits COVID-19 patients remains debatable. In critical COVID-19 patients, the excessive accumulation of cytokines may occur, and this can lead to a fatal outcome. Previous studies have revealed that the levels of pro-inflammatory cytokines/chemokines including interleukin-2 (IL-2), interleukin-6 (IL-6), granulocyte colony stimulating factor (GCSF), IFN- γ inducible protein 10, monocyte chemoattractant protein 1 (MCP-1),

macrophage inflammatory protein 1A, tumor necrosis factor- α (TNF- α) were observed to be higher in patients critically ill with COVID-19 compared to those with mild-moderate disease.^{24,25} TPE is a therapeutic procedure principally acting to remove (through double filtration) molecules of 60–140 nm in size.⁵ The molecule size of pro-inflammatory cytokines/chemokines is 80–220 nm.²⁶ Therefore, the elimination of pro-inflammatory cytokines/chemokines, proven to affect those critically ill with COVID-19 might provide benefits to improve the prognosis of COVID-19 patients. Moreover, a previous study also reported that TPE played an important role in eliminating toxic substances by suppressing the cytokine release syndrome.²⁷ It was also suggested that TPE plays a crucial role in restoring normal substances that may be deficient in the plasma,⁵ leading to stabilization and restoration of endothelial membranes.²⁸ Another possibility is when fresh frozen plasma was used in fluid replacement; TPE was associated with the improvement of coagulopathy in COVID-19 patients.²⁹ Previous evidence suggests that TPE might play an important role in maintaining the balance between anti and pro-inflammatory cytokines in the plasma, and might rectify the prognosis in patients with COVID-19, as reported in our study.

To the best of our knowledge, our study is the first meta-analysis reporting the benefit of TPE in reducing the mortality rate of critically ill COVID-19 patients. We found that COVID-19 patients treated with TPE had a lower risk of mortality compared to those without TPE treatment. Since COVID-19 guidelines suggest that the use of TPE for patients with COVID-19 should be carefully implemented as the evidence of TPE efficacy was only limited to a case report,³ our current findings might strengthen the evidence that the use of TPE is effective in reducing the risk of mortality among patients with COVID-19. However, in real-world implementation, special settings such as appropriate condition, target of treatment, potential complications, and particular case or comorbidity should be investigated.

Since this is the initial evidence on the potential efficacy of TPE for the management of COVID-19, several limitations should be highlighted. First, we did not include any potential confounding factors such as comorbidity, the levels of proinflammatory cytokines, and onset of disease course to describe the association between TPE and the risk of mortality rate. Second, a limited number of investigations on the use of TPE in COVID-19 management resulted in our study including only a limited number of articles. Therefore, further investigation involving a larger sample size is required. Third, the clinical setting on the use of TPE might differ among studies, and therefore, this variation might also govern the potency of bias. Fourth, among the included studies, we obtained only one randomized control trial (RCT) and three observational studies. Further meta-analyses involving only RCT studies might provide better levels of evidence.

Conclusion

The data suggests that the use of TPE for the management of critically ill COVID-19 patients could reduce the mortality rate. The application of TPE for the management of COVID-19 should be considered in well-equipped hospitals.

Data availability

Underlying data

All data underlying the results are available as part of the article and no additional source data are required.

Reporting guidelines

Figshare: PRISMA checklist for 'the association between therapeutic plasma exchange and the risk of mortality among patients with critically ill COVID-19: a meta-analysis. <https://doi.org/10.6084/m9.figshare.16622572.v1>¹⁶

Data are available under the terms of the [Creative Commons Attribution 4.0 International license](#) (CC-BY 4.0).

Acknowledgements

We thank Lembaga Pengelola Dana Pendidikan (LPDP) Republic of Indonesia for supporting this project.

References

1. Wang C, Horby PW, Hayden FG, et al.: **A novel coronavirus outbreak of global health concern.** *Lancet.* 2020; **395**: 470–473. [PubMed Abstract](#) | [Publisher Full Text](#)
2. Coccia M: **The impact of first and second wave of the COVID-19 pandemic in society: comparative analysis to support control measures to cope with negative effects of future infectious diseases.** *Environ Res.* 2021; **197**: 111099. [PubMed Abstract](#) | [Publisher Full Text](#)
3. Rochwerg B, Agarwal A, Siemieniuk RA, et al.: **A living WHO guideline on drugs for covid-19.** *BMJ.* 2020; **370**: m3379.
4. Salluh JIF, Arabi YM, Binnie A: **COVID-19 research in critical care: the good, the bad, and the ugly.** *Intensive Care Med.* 2021; **47**:

- 470–472.
[PubMed Abstract](#) | [Publisher Full Text](#)
5. Simon TL, Snyder EL, Stowell CP, *et al.*: *Rossi's principles of transfusion medicine*. John Wiley & Sons; 2009.
[Publisher Full Text](#)
 6. Dundas S, Murphy J, Soutar RL, *et al.*: **Effectiveness of therapeutic plasma exchange in the 1996 Lanarkshire *Escherichia coli* O157:H7 outbreak.** *Lancet*. 1999; **354**: 1327–1330.
[PubMed Abstract](#) | [Publisher Full Text](#)
 7. Brocklebank V, Wong EK, Fielding R, *et al.*: **Atypical haemolytic uraemic syndrome associated with a CD46 mutation triggered by *Shigella flexneri*.** *Clin Kidney J*. 2014; **7**: 286–288.
[PubMed Abstract](#) | [Publisher Full Text](#)
 8. Burakovskii NI, Sviridchuk VM: **A case using plasmapheresis in treating infectious toxicosis in young infants.** *Pediatrics*. 1988; **98**: 98–99.
[PubMed Abstract](#)
 9. Keith PD, Wells AH, Hodges J, *et al.*: **The therapeutic efficacy of adjunct therapeutic plasma exchange for septic shock with multiple organ failure: a single-center experience.** *Crit Care*. 2020; **24**: 518.
[PubMed Abstract](#) | [Publisher Full Text](#)
 10. Tabibi S, Tabibi T, Conic RRZ, *et al.*: **Therapeutic Plasma Exchange: A potential Management Strategy for Critically Ill COVID-19 Patients.** *J Intensive Care Med*. 2020; **35**: 827–835.
[PubMed Abstract](#) | [Publisher Full Text](#)
 11. Khamis F, Al-Zakwani I, Al Hashmi S, *et al.*: **Therapeutic plasma exchange in adults with severe COVID-19 infection.** *Int J Infect Dis*. 2020; **99**: 214–218.
[PubMed Abstract](#) | [Publisher Full Text](#)
 12. Gucyetmez B, Atalan HK, Sertdemir I, *et al.*: **Therapeutic plasma exchange in patients with COVID-19 pneumonia in intensive care unit: a retrospective study.** *Crit Care*. 2020; **24**: 492.
[PubMed Abstract](#) | [Publisher Full Text](#)
 13. Kamran SM, Mirza ZE, Naseem A, *et al.*: **Therapeutic plasma exchange for coronavirus disease-2019 triggered cytokine release syndrome: a retrospective propensity matched control study.** *PLoS One*. 2021; **16**: e0244853.
[PubMed Abstract](#) | [Publisher Full Text](#)
 14. Faqih F, Alharthy A, Abdulaziz S, *et al.*: **Therapeutic plasma exchange in patients with life-threatening COVID-19: a randomised controlled clinical trial.** *Int J Antimicrob Agents*. 2021; **57**: 106334.
[PubMed Abstract](#) | [Publisher Full Text](#)
 15. Liberati A, Altman DG, Tetzlaff J, *et al.*: **The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration.** *BMJ*. 2009; **339**: b2700.
[PubMed Abstract](#) | [Publisher Full Text](#)
 16. Fajar J, *et al.*: **The association between therapeutic plasma exchange and the risk of mortality among patients with critically ill COVID-19: a meta-analysis.** Figshare. Dataset. 2021.
[Publisher Full Text](#)
 17. Stang A: **Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses.** *Eur J Epidemiol*. 2010; **25**: 603–605.
[PubMed Abstract](#) | [Publisher Full Text](#)
 18. Olivo SA, Macedo LG, Gadotti IC, *et al.*: **Scales to assess the quality of randomized controlled trials: a systematic review.** *Phys Ther*. 2008; **88**: 156–175.
[Publisher Full Text](#)
 19. Liu J, Liu S: **The management of coronavirus disease 2019 (COVID-19).** *J Med Virol*. 2020; **92**: 1484–1490.
[PubMed Abstract](#) | [Publisher Full Text](#)
 20. Downes KA, Allen K, Sarode R, *et al.*: **Consanguineous hemolytic uremic syndrome secondary to *Escherichia coli* O157:H7 infection treated with aggressive therapeutic plasma exchange.** *J Clin Apher*. 2001; **16**: 155–156.
[PubMed Abstract](#) | [Publisher Full Text](#)
 21. Reiss RF, Rubinstein P, Friedman-Kien A, *et al.*: **Partial plasma exchange in patients with AIDS and Kaposi's sarcoma. Plasmapheresis in AIDS.** *AIDS Res*. 1986; **2**: 183–190.
[PubMed Abstract](#) | [Publisher Full Text](#)
 22. Salim YS, Faber V, Skinhoj P, *et al.*: **Plasmapheresis in the treatment of peripheral HIV neuropathy.** *Ugeskr Laeger*. 1989; **151**: 1754–1756.
[PubMed Abstract](#)
 23. Bollee G, Touzot M, Mechali F, *et al.*: **Plasma exchange for disseminated cryptococcosis.** *Am J Kidney Dis*. 2009; **53**: 673–676.
[PubMed Abstract](#) | [Publisher Full Text](#)
 24. Huang C, Wang Y, Li X, *et al.*: **Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.** *Lancet*. 2020; **395**: 497–506.
[PubMed Abstract](#) | [Publisher Full Text](#)
 25. Channappanavar R, Perlman S: **Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology.** *Semin Immunopathol*. 2017; **39**: 529–539.
[PubMed Abstract](#) | [Publisher Full Text](#)
 26. Strauss RG, Ciavarella D, Gilcher RO, *et al.*: **An overview of current management.** *J Clin Apher*. 1993; **8**: 189–194.
[Publisher Full Text](#)
 27. Padmanabhan A, Connelly-Smith L, Aquil N, *et al.*: **Guidelines on the Use of Therapeutic Apheresis in Clinical Practice - Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Eighth Special Issue.** *J Clin Apher*. 2019; **34**: 171–354.
[PubMed Abstract](#) | [Publisher Full Text](#)
 28. Bar-On YM, Flamholz A, Phillips R, *et al.*: **SARS-CoV-2 (COVID-19) by the numbers.** *Elife*. 2020; **9**.
[PubMed Abstract](#) | [Publisher Full Text](#)
 29. Zachariah U, Nair SC, Goel A, *et al.*: **Targeting raised von Willebrand factor levels and macrophage activation in severe COVID-19: Consider low volume plasma exchange and low dose steroid.** *Thromb Res*. 2020; **192**: 2.
[PubMed Abstract](#) | [Publisher Full Text](#)

Open Peer Review

Current Peer Review Status:

Version 1

Reviewer Report 13 January 2022

<https://doi.org/10.5256/f1000research.78779.r116276>

© 2022 Kumar A. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Ashish Kumar

Department of Critical Care Medicine, St Johns's Medical College Hospital, Bangalore, Karnataka, India

Wardhani et al., in their study titled "The association between therapeutic plasma exchange and the risk of mortality among patients critically ill with COVID-19: a meta-analysis" reported therapeutic plasma exchange to be of benefit in patients with critically ill COVID-19. I have the following comments.

Introduction

-None

Methods

- What was the statistical method used to pool data? Random/Fixed effect? What was the measure of Tau2 if IV method was used for pooling?

Results

- Summarize the quality of the included studies.
- Use GRADE criteria to grade the level of evidence.
- Baseline Table, Table 1 needs to be elaborated more with more variables to give the reader an idea about the severity of the illness among patients included.

Discussion

- The discussion needs to stress the "low quality" of included studies considering the observational nature of the study.

Are the rationale for, and objectives of, the Systematic Review clearly stated?

Yes

Are sufficient details of the methods and analysis provided to allow replication by others?

No

Is the statistical analysis and its interpretation appropriate?

Partly

Are the conclusions drawn adequately supported by the results presented in the review?

Partly

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: Needs more methodological clarification.

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.

Reviewer Report 10 January 2022

<https://doi.org/10.5256/f1000research.78779.r116268>

© 2022 Gachabayov M. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Mahir Gachabayov

Section of Colorectal Surgery, Department of Surgery, Westchester Medical Center, New York Medical College, Valhalla, NY, USA

Editorial Note from F1000Research – 31st March 2023:

This report has been updated to include a conflict of interest statement which was not declared at the time of publishing of this report.

Thank you for the opportunity of reviewing this manuscript.

This is a systematic review and meta-analysis aiming at evaluating the use of therapeutic plasma exchange (TPE) in terms of mortality in critically ill COVID-19 patients as compared to a control group. The research question makes sense and is worth exploring as this topic has been speculated upon with anecdotal evidence.

The methodology of meta-analysis is adequate. The literature search was comprehensive; study screening and selection process as well as data extraction complied with PRISMA guidelines. Statistical analysis was adequate. Discussion is comprehensible and easy to read.

Conclusion drawn was partly justified by the findings of the analysis. I would evaluate certainty of evidence generated in this meta-analysis on a GRADE scale. If certainty of evidence is assessed to be low (given the limitations), I would conclude that although TPE could reduce mortality as the findings of this study suggest, current evidence is inconclusive.

Are the rationale for, and objectives of, the Systematic Review clearly stated?

Yes

Are sufficient details of the methods and analysis provided to allow replication by others?

Yes

Is the statistical analysis and its interpretation appropriate?

Partly

Are the conclusions drawn adequately supported by the results presented in the review?

Partly

Competing Interests: This reviewer previously published an article with the authors in December 2021, one month before their review on this article. The reviewer confirms that this was an international project with multiple authors and their previous collaboration did not bias their review in any way.

Reviewer Expertise: clinical outcomes and evidence synthesis

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Reviewer Report 06 January 2022

<https://doi.org/10.5256/f1000research.78779.r116284>

© 2022 Wendt G. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Guilherme Welter Wendt

Psychologist and Adjunct Professor of Quantitative Research Methods, Centro de Ciências da Saúde (CCS), Universidade Estadual do Oeste do Paraná (UNIOESTE), Francisco Beltrão, Brazil

Editorial Note from F1000Research – 31st March 2023:

This report has been updated to include a conflict of interest statement which was not declared at the time of publishing of this report.

- References are needed to support these statements: "Patients critically ill with COVID-19 have been widely reported to have a poor prognosis, and theory reveals that cytokine storm might underlie this mechanism. In a cytokine storm excessive accumulation of pro-inflammatory cytokines might be responsible for the poor prognosis of COVID-19 patients".

- "No study has found an effective treatment for the management of a cytokine storm in patients critically ill with COVID-19" - how can you prove that? Perhaps it could be informative to tone down this sentence, including "to the best of our knowledge" or provide dates and keywords used in

scientific databases that resulted in zero studies.

- These sentences could be merged, resulting in an objective, clear paragraph: "However, insufficient evidence has resulted in indecision in applying TPE for the management of critically ill COVID-19 patients. To date, TPE has been studied in Oman,¹¹ Turkey,¹² Pakistan,¹³ and Saudi Arabia.¹⁴ However, contradictory findings exist".
- Under the search strategy and data extraction, please state which authors performed these tasks (as reported for the assessment methodological quality). What happened when disagreements occurred?
- The Jada-modified scale does not appear under the section "Eligibility criteria". Should you include, like you did with the NOS?
- In the results, you mention that studies with insufficient data were excluded. Should this appear in your inclusion/exclusion criteria too?
- The following sentence seems incomplete: "Our analysis revealed the absence of the evidence of heterogeneity. Therefore, we applied a fixed-effect model to assess the correlation". Correlation between what?
- The first paragraph of the discussion looks a little bit repetitive. The third paragraph also seems to repeat some of the information given at the beginning of the discussion.
- "Previous evidence suggests that TPE might play an important role in maintaining the balance between anti and pro-inflammatory cytokines in the plasma, and might rectify the prognosis in patients with COVID-19, as reported in our study". Can you show us (cite) the evidence mentioned?
- "our current findings might strengthen the evidence that the use of TPE is effective in reducing the risk of mortality among patients with COVID-19". Here you are not talking about severe Covid. Does it mean that TPE might benefit mild/moderate cases too?

Are the rationale for, and objectives of, the Systematic Review clearly stated?

Yes

Are sufficient details of the methods and analysis provided to allow replication by others?

Yes

Is the statistical analysis and its interpretation appropriate?

Yes

Are the conclusions drawn adequately supported by the results presented in the review?

Yes

Competing Interests: This reviewer previously published an article with the authors in December 2021, one month before their review on this article. The reviewer confirms that their previous collaboration did not bias their review in any way.

Reviewer Expertise: Public health, epidemiology, statistics

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.

Reviewer Report 23 December 2021

<https://doi.org/10.5256/f1000research.78779.r116258>

© 2021 Enitan S. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Seyi Samson Enitan

Department of Medical Laboratory Science, Babcock University, Ilishan-Remo, Nigeria

Editorial Note from F1000Research – 31st March 2023:

This report has been updated to include a conflict of interest statement which was not declared at the time of publishing of this report.

This paper contributes considerably to knowledge in the field of COVID-19 management. The introduction is considered satisfactory. The authors provided background that puts the manuscript into context and allows readers outside the field to understand the purpose and significance of the study. They also identified the existing gap in knowledge that needs to be filled. The rationale for, and objectives of, the systematic review were clearly stated.

In this manuscript, the authors assessed the association between therapeutic plasma exchange (TPE) and the reduction of mortality of critically ill COVID-19 patients. A meta-analysis was conducted by collecting data from PubMed, Scopus, and Web of Science, in which a total of four papers were assessed. The methodology section was clearly presented to allow the reproduction of the study. Sufficient details of the analysis were also provided to allow replication by others. The statistical analysis and its interpretation were appropriate.

The outcome of the study shows that critically ill COVID-19 patients treated with TPE had a lower risk of mortality compared to those without TPE treatment (OR: 0.21; 95% CI: 0.05, 0.85). Hence, the need for TPE advocacy with recourse to the clinical presentation of the patient.

The study, however, is not without its attending limitations, mainly:

1. Potential confounding factors such as comorbidity, the levels of pro-inflammatory cytokines, and the onset of disease course to describe the association between TPE and the risk of mortality rate were not included.
2. The sample size was small due to the limited number of papers assessed.
3. Bias due to variation in clinical setting in the use of TPE

4. Only one randomized control trial was included in the study.

The conclusion drawn was adequately supported by the data assessed in the meta-analysis.

In all, the work is okay and the findings are worth sharing with the scientific community, however, it is important to note that the use of TPE must be done with utmost caution to forestall unexpected complications that may be associated with it.

NB: Authors should declare whether competing interests exist or not.

Are the rationale for, and objectives of, the Systematic Review clearly stated?

Yes

Are sufficient details of the methods and analysis provided to allow replication by others?

Yes

Is the statistical analysis and its interpretation appropriate?

Yes

Are the conclusions drawn adequately supported by the results presented in the review?

Yes

Competing Interests: This reviewer previously published two articles with the authors in August and December 2021, prior to their review on this article. The reviewer confirms that this was a genuine mistake as they had not previously collaborated with the corresponding or first authors of this article. This did not bias their review in any way.

Reviewer Expertise: Immunology of infectious diseases including COVID-19, HIV/AIDS and Opportunistic infections

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

The benefits of publishing with F1000Research:

- Your article is published within days, with no editorial bias
- You can publish traditional articles, null/negative results, case reports, data notes and more
- The peer review process is transparent and collaborative
- Your article is indexed in PubMed after passing peer review
- Dedicated customer support at every stage

For pre-submission enquiries, contact research@f1000.com

F1000Research